Product Overview
[Drug Name]
Generic Name: Teprenone Capsules
Trade Name: Shiweishu
English Name: Teprenone Capsules
Chinese Pinyin: Tipuritong Jiaonang
[Ingredients]
Teprenone. Molecular Weight: C23H38O
[Properties]
This product is a hard capsule containing white or slightly yellow granules and powder.
[Indications]
1. Improvement of gastric mucosal lesions (erosion, bleeding, flushing, edema) in acute gastritis and acute exacerbation of chronic gastritis.
2. Gastric ulcer.
[Dosage and Administration]
The recommended dosage for adults is 50 mg (one capsule) orally three times a day after meals.
[Adverse Reactions]
Among the 10,914 cases, 52 (0.48%) experienced adverse reactions (as of the end of the reexamination). (1) Clinically serious adverse reactions (frequency unknown), liver dysfunction and jaundice. Liver dysfunction may cause an increase in AST (GOT), AST (GPT), gamma-GTP or Al-P, and jaundice may occur. Once the above abnormalities occur, the drug should be discontinued and appropriate measures should be taken. (2) Other adverse reactions, digestive system: constipation, diarrhea, vomiting, thirst, abdominal pain, abdominal distension (30.1%); mental and nervous system: headache (<0.1%). Allergic note: rash, itching (<0.1%). Others: increased total cholesterol, redness or heat in the eyelids (<0.1%). Thrombocytopenia (frequency unknown).
[Contraindications]
Use with caution in pregnant women and children.
[Precautions]
Discontinue use in the above situations. Please read the instructions carefully and use according to the doctor's advice.
[Special population use]
Precautions for children: Use with caution in children.
Precautions for pregnancy and lactation: Use with caution in pregnant women. When administering this medication to pregnant women or women who may become pregnant, the benefits and risks should be weighed.
Precautions for Elderly Patients: Generally, the physiological metabolic function of the elderly is reduced, so a reduced dosage should be used.
[Drug Interactions]
Not yet established.
[Pharmacological Actions]
1. Cytoprotective Effects Due to Induction of Heat Shock Protein (HSP) Production: Teprenone induces the production of HSP60, 70, and 90 in guinea pig gastric mucosal cells and exhibits cytoprotective effects. 2. Increasing Gastric Mucosal Prostaglandin Production: Teprenone increases the levels of prostaglandin E2 and I2 in the gastric mucosa of rats. This is achieved by increasing the activity of prostaglandin biosynthetic enzymes. 3. Increasing and Improving Gastric Mucosal Blood Flow: Teprenone increases gastric mucosal blood flow. Teprenone also improves gastric mucosal blood flow in rats subjected to water immersion restraint stress. 4. Protective Effects on the Gastric Mucosa: Teprenone inhibits ethanol-induced gastric mucosal damage in rats. Teprenone inhibits ethanol-induced gastric mucosal damage in healthy adult men. 5. Maintaining the stability of the proliferative zone of gastric mucosal cells: Teprenone ameliorates the decreased proliferation of gastric mucosal cells in mice induced by hydrocortisone, thereby maintaining the stability of the proliferative zone of gastric mucosal cells. It also enhances the regenerative capacity of the gastric mucosa and promotes the repair of gastric mucosal damage in rats induced by acetic acid-induced experimental ulcers. 6. Inhibiting lipid peroxidation: Teprenone inhibits gastric mucosal damage caused by burns and increased lipid peroxides in the gastric mucosa in rats.
[Storage]
Store at room temperature.
[Specifications]
50 mg/tablet
[Packaging]
20 tablets/box
[Expiration Date]
36 months
[Approval Number]
National Medicine Standard H20093656
[Manufacturer]
Eisai (China) Pharmaceutical Co., Ltd.
